AI Summary
✦ ClarthaPI Industries is an agricultural chemicals and pharmaceuticals manufacturer serving India and international markets. Agrochemicals drive revenue through insecticides, fungicides, herbicides, biologicals, crop solutions, plant nutrients, and specialty chemicals. Custom synthesis and manufacturing adds outsourced production, while pharmaceuticals contribute medicinal and botanical products. Shares rose 2% as investors assessed FY26 results, but the development has yet to offset 15.6% revenue contraction. Profit declined 20.4% year-on-year despite improving margins, indicating cost benefits amid weaker demand. ROE is 12.3%, while debt/equity of 3.05 means leverage materially amplifies returns and financial risk. At 31.8x earnings, the stock appears rich relative to its current negative growth profile. The key open question is whether margin improvement can precede a durable recovery in agrochemical volumes and earnings.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 25 analysts
Fundamentals
Fundamentals institutional score is 35 using EVA spread proxy 0.3%; growth durability 8.9.
Valuation
Valuation institutional score is 96 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 39 using mean target upside 16.8%; dispersion penalty 30; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 76 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Neutral. valuation and technical structure provide support, while fundamentals and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 23.6% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -1.76). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹107.54. Applying the stock's normalized valuation corridor produces a fair range of ₹4,053.18 to ₹4,714.55, with base value near ₹4,451.08 (+63.0% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹107.54
Forward P/E
25.4x
Base Fair Value
₹4,451.08
Fair Range
₹4,053.18 - ₹4,714.55
Upside To Base
+63.0%
Estimate Source
Live forward EPS
Growth Estimate
-39.4%
5Y Average
38.70
Current
31.60
Overvalued
43.84
Undervalued
37.69
5Y Average
28.89
Current
23.59
Overvalued
31.25
Undervalued
25.68
5Y Average
4.69
Current
3.69
Overvalued
5.39
Undervalued
3.98
Peers & Comparison
Sector: Materials · Theme: Diversified Chemicals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
GODREJ INDUSTRIES LTD GODREJINDDiversified Chemicals | +9.9% | 5.2% | 35.0x Undervalued | -58% vs avg | +19.7% |
BASF INDIA LTD BASFDiversified Chemicals | +24.5% | 4.0% | 28.3x Undervalued | -66% vs avg | -11.9% |
SRF LTD SRFDiversified Chemicals | +31.8% | 12.7% | 35.3x Undervalued | -58% vs avg | -8.3% |
PIDILITE INDUSTRIES LTD PIDILITINDDiversified Chemicals | +21.3% | 17.2% | 65.1x Undervalued | -23% vs avg | +7.0% |
TATA CHEMICALS LTD TATACHEMDiversified Chemicals | +14.4% | -14.3% | — | — | -29.2% |
SUDARSHAN CHEMICAL INDS L SUDARSCHEMDiversified Chemicals | +106.7% | 0.2% | 389.5x Premium | +363% vs avg | -20.8% |
ATUL LTD ATULDiversified Chemicals | +25.0% | 12.0% | 25.3x Undervalued | -70% vs avg | +5.0% |
DCM SHRIRAM LIMITED DCMSHRIRAMDiversified Chemicals | +9.3% | 10.4% | 11.0x Undervalued | -87% vs avg | -24.3% |
PI INDUSTRIES LTD trades at a discount (31.6x vs peer avg 84.2x), suggesting potential undervaluation relative to the Diversified Chemicals cohort. Peers include GODREJ INDUSTRIES LTD, BASF INDIA LTD, SRF LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.39K CrMar 2026Latest net profit
₹198 CrMar 2026Latest EPS
₹13.04Mar 2026Net margin
28.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,506 | 1,829 | 1,969 | 1,721 | 1,626 | 2,012 | 2,131 | 1,780 | 1,648 | 1,769 | 1,753 | 1,270 | 1,391 |
| Expenses + | 1,172 | 1,354 | 1,415 | 1,177 | 1,173 | 1,381 | 1,446 | 1,235 | 1,144 | 1,195 | 1,146 | 900 | 1,006 |
| Operating Profit | 334 | 475 | 553 | 544 | 453 | 631 | 685 | 545 | 504 | 574 | 607 | 370 | 385 |
| OPM % | 22% | 26% | 28% | 32% | 28% | 31% | 32% | 31% | 31% | 32% | 35% | 29% | 28% |
| Other Income + | 53 | 47 | 56 | 65 | 56 | 69 | 90 | 73 | 68 | 80 | 80 | 56 | -41 |
| Interest | 2 | 2 | 2 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 2 |
| Depreciation | 56 | 59 | 63 | 62 | 62 | 65 | 66 | 67 | 65 | 71 | 72 | 78 | 85 |
| Profit before tax | 328 | 462 | 545 | 545 | 443 | 634 | 708 | 548 | 506 | 582 | 615 | 345 | 258 |
| Tax % | 15% | 14% | 15% | 11% | 13% | 21% | 21% | 23% | 24% | 20% | 20% | 18% | 23% |
| Net Profit + | 279 | 395 | 464 | 486 | 384 | 498 | 558 | 424 | 386 | 464 | 491 | 282 | 198 |
| EPS in Rs | 18.42 | 26.05 | 30.62 | 32.07 | 25.34 | 32.85 | 36.81 | 27.93 | 25.43 | 30.60 | 32.37 | 18.56 | 13.04 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Consideration And Approval Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter Ended June 30, 2026